Talphera sells DSUVIA/DZUVEO royalty rights to XOMA for $8M upfront

TALPHERA, INC.

Sold rights to royalty and milestone payments from Vertical Pharma to XOMA for $8M cash.
Potential milestones up to $116.5M based on net sales; Talphera retains partial rights after stepdown.
Stepdown occurs when XOMA receives a minimum payment amount; specific amount not disclosed.
After stepdown: Talphera keeps 50% of DoD sales royalties and milestones; XOMA gets 100% non-DoD.
Agreement includes customary reps, warranties, and indemnification obligations.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

TALPHERA, INC. entered into Payment Interest Purchase Agreement with XOMA (US) LLC valued at $8 million (effective 2024-01-12).

Action: entry
Agreement: asset purchase
Counterparty: XOMA (US) LLC
Value: $8 million
Effective: 2024-01-12

Exact text from the filing

On January 12, 2024, Talphera, Inc. (the “Company”) and XOMA (US) LLC (“XOMA”) entered into a Payment Interest Purchase Agreement (the “Purchase Agreement”) for the sale by the Company to XOMA, in exchange for $8 million, of the Company’s right, title and interest in and to certain amounts payable to the Company (collectively, the “Purchased Receivables”)

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

TALPHERA, INC. filing history →

Source: SEC EDGAR

accession 0001437749-24-001579

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.